In the evolving landscape of diabetes management, novel therapies like semaglutide and retatrutide are gaining traction. These agents, belonging to the glucagon-like peptide-1 (GLP-1) receptor agonist class, offer https://sahilxynh117051.thelateblog.com/39469842/semaglutide-vs-retatrutide-a-novel-comparison-in-diabetes-management